Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10384MR)

This product GTTS-WQ10384MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Autoimmune diseases, Rheumatoid arthritis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10384MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11304MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-522
GTTS-WQ4947MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ13727MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RC48-0
GTTS-WQ9918MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ15915MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ12964MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ11011MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ15669MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VB6-845
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW